Colorectal cancer microenvironment: Among nutrition, gut microbiota, inflammation and epigenetics

Current Pharmaceutical Design

Volumn 19, Issue 4, 2013, Pages 765-778

  Garagnani, Paolo ^a   Pirazzini, Chiara ^a   Franceschi, Claudio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Aging; Colorectal cancer; Epigenetic; Gut microbiota; Inflammation; Nutrition

Indexed keywords

BIOLOGICAL MARKER; DNA;

AGING; ANATOMY; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER THERAPY; CARCINOGENESIS; COLORECTAL CANCER; DNA DAMAGE; DNA METHYLATION; EPIGENETICS; FOOD; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INTESTINE CELL; INTESTINE CRYPT; INTESTINE EPITHELIUM; INTESTINE FLORA; MORBIDITY; MORTALITY; MUTATION; NONHUMAN; NUTRITION; ONCOGENE; PRIORITY JOURNAL; RISK FACTOR; TUMOR MICROENVIRONMENT;

EID: 84876742643     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804581981     Document Type: Article

References (204)

1. Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 2009; 10: 353-8.
2. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev 2007; 21: 2525-38.
3. Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 2008; 14: 3937-47.
4. Kraus S, Arber N. Inflammation and colorectal cancer. Curr Opin Pharmacol 2009; 9: 405-10.
5. Willett WC. Diet and breast cancer. J Intern Med 2001; 249: 395-411.
6. Habito RC, Ball MJ. Postprandial changes in sex hormones after meals of different composition. Metabolism 2001; 50: 505-11.
7. Key TJ, Allen NE, Spencer EA, Travis RC. Nutrition and breast cancer. Breast 2003; 12: 412-6.
8. Stoll BA. Nutrition and breast cancer risk: can an effect via insulin resistance be demonstrated? Breast Cancer Res Treat 1996; 38: 239-46.
9. Willett WC. Diet and cancer. Oncologist 2000; 5: 393-404.
10. Stemmermann GN, Nomura AM, Chyou PH, Kato I, Kuroishi T. Cancer incidence in Hawaiian Japanese: migrants from Okinawa compared with those from other prefectures. Jpn J Cancer Res 1991; 82: 1366-70.
11. Kolonel LN, Altshuler D, Henderson BE. The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer 2004; 4: 519-27.
12. Hall PA, Coates PJ, Ansari B, Hopwood D. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci 1994; 107 (Pt 12): 3569-77.
13. Potten CS, Owen G, Booth D. Intestinal stem cells protect their genome by selective segregation of template DNA strands. J Cell Sci 2002; 115: 2381-8.
14. Brittan M, Wright NA. Stem cell in gastrointestinal structure and neoplastic development. Gut 2004; 53: 899-910.
15. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
16. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. Gastrointest Cancer Res 2012; 5: 19-27.
17. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000; 103: 311-20.
18. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma. Science 1997; 275: 1784-7.
19. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-90.
20. Brentnall TA, Crispin DA, Rabinovitch PS, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994; 107: 369-78.
21. Biswas S, Chytil A, Washington K, et al. Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res 2004; 64: 4687-92.
22. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008; 135: 1079-99.
23. Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 1998; 92: 645-56.
24. Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008; 3: e3698.
25. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
26. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101: 1308-24.
27. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-60.
28. Mammano E, Belluco C, Bonafe M, et al. Association of p53 polymorphisms and colorectal cancer: modulation of risk and progression. Eur J Surg Oncol 2009; 35: 415-9.
29. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003; 21: 1174-9.
30. Neri S, Gardini A, Facchini A, et al. Mismatch repair system and aging: microsatellite instability in peripheral blood cells from differently aged participants. J Gerontol A Biol Sci Med Sci 2005; 60: 285-92.
31. Sobin LH, Gospodarowicz MK, Wittekind C, International Union against Cancer. TNM classification of malignant tumours. Wiley-Blackwell: Chichester, West Sussex, UK; Hoboken, NJ 2010.
32. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375: 1624-33.
33. Bretthauer M. Evidence for colorectal cancer screening. Best Pract Res Clin Gastroenterol 2010; 24: 417-25.
34. van Dam L, Kuipers EJ, van Leerdam ME. Performance improvements of stool-based screening tests. Best Pract Res Clin Gastroenterol 2010; 24: 479-92.
35. Bonafe M, Storci G, Franceschi C. Inflamm-aging of the stem cell niche: breast cancer as a paradigmatic example: breakdown of the multi-shell cytokine network fuels cancer in aged people. Bioessays 2012; 34: 40-9.
36. Franceschi C, Bonafe M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000; 908: 244-54.
37. Franceschi C, Capri M, Monti D, et al. Inflammaging and antiinflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007; 128: 92-105.
38. Franceschi C, Bonafe M, Valensin S. Human immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space. Vaccine 2000; 18: 1717-20.
39. Capri M, Monti D, Salvioli S, et al. Complexity of antiimmunosenescence strategies in humans. Artif Organs 2006; 30: 730-42.
40. Franceschi C, Valensin S, Fagnoni F, Barbi C, Bonafe M. Biomarkers of immunosenescence within an evolutionary perspective: the challenge of heterogeneity and the role of antigenic load. Exp Gerontol 1999; 34: 911-21.
41. Pennesi G, Liu Z, Ciubotariu R, et al. TCR repertoire of suppressor CD8+CD28-T cell populations. Hum Immunol 1999; 60: 291-304.
42. Wack A, Cossarizza A, Heltai S, et al. Age-related modifications of the human alphabeta T cell repertoire due to different clonal expansions in the CD4+ and CD8+ subsets. Int Immunol 1998; 10: 1281-8.
43. Foster AD, Sivarapatna A, Gress RE. The aging immune system and its relationship with cancer. Aging health 2011; 7: 707-18.
44. Dall'Olio F, Malagolini N, Trinchera M, Chiricolo M. Mechanisms of cancer-associated glycosylation changes. Front Biosci 2012; 17: 670-99.
45. Vanhooren V, Dewaele S, Libert C, et al. Serum N-glycan profile shift during human ageing. Exp Gerontol 2010; 45: 738-43.
46. Dall'olio F, Vanhooren V, Chen CC, Slagboom PE, Wuhrer M, Franceschi C. N-glycomic biomarkers of biological aging and longevity: A link with inflammaging. Ageing Res Rev 2012.
47. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts (*). Annu Rev Immunol 2012; 30: 677-706.
48. Ostan R, Bucci L, Capri M, et al. Immunosenescence and immunogenetics of human longevity. Neuroimmunomodulation 2008; 15: 224-40.
49. Cevenini E, Caruso C, Candore G, et al. Age-related inflammation: the contribution of different organs, tissues and systems. How to face it for therapeutic approaches. Curr Pharm Des 2010; 16: 609-18.
50. Salvioli S, Capri M, Santoro A, et al. The impact of mitochondrial DNA on human lifespan: a view from studies on centenarians. Biotechnol J 2008; 3: 740-9.
51. Biagi E, Nylund L, Candela M, et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One 2010; 5: e10667.
52. Vescovini R, Biasini C, Telera AR, et al. Intense antiextracellular adaptive immune response to human cytomegalovirus in very old subjects with impaired health and cognitive and functional status. J Immunol 2010; 184: 3242-9.
53. Mishto M, Santoro A, Bellavista E, Bonafe M, Monti D, Franceschi C. Immunoproteasomes and immunosenescence. Ageing Res Rev 2003; 2: 419-32.
54. Motta M, Bennati E, Vacante M, et al. Autopsy reports in extreme longevity. Arch Gerontol Geriatr 2010; 50: 48-50.
55. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
56. Meira LB, Bugni JM, Green SL, et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest 2008; 118: 2516-25.
57. Westbrook AM, Wei B, Braun J, Schiestl RH. Intestinal mucosal inflammation leads to systemic genotoxicity in mice. Cancer Res 2009; 69: 4827-34.
58. Kryston TB, Georgiev AB, Pissis P, Georgakilas AG. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res 2011; 711: 193-201.
59. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-59.
60. Kojima M, Morisaki T, Sasaki N, et al. Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res 2004; 24: 675-81.
61. Naugler WE, Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 2008; 18: 19-26.
62. Galizia G, Orditura M, Romano C, et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 2002; 102: 169-78.
63. Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 2003; 83: 222-6.
64. Kai H, Kitadai Y, Kodama M, et al. Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma. Anticancer Res 2005; 25: 709-13.
65. Matthews VB, Allen TL, Risis S, et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 2010; 53: 2431-41.
66. Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, Lahm H. Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett 2000; 151: 31-8.
67. Belluco C, Olivieri F, Bonafe M, et al. 174 G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res 2003; 9: 2173-6.
68. Yu Y, Wang W, Zhai S, Dang S, Sun M. IL6 gene polymorphisms and susceptibility to colorectal cancer: a meta-analysis and review. Mol Biol Rep 2012; 39: 8457-63.
69. Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 transsignaling. Immunity 2004; 21: 491-501.
70. Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitisassociated cancer. Cancer Cell 2009; 15: 103-13.
71. Matsumoto S, Hara T, Mitsuyama K, et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol 2010; 184: 1543-51.
72. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
73. Takeda K, Clausen BE, Kaisho T, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999; 10: 39-49.
74. Madison BB, Dunbar L, Qiao XT, Braunstein K, Braunstein E, Gumucio DL. Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J Biol Chem 2002; 277: 33275-83.
75. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NFkappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010; 21: 11-9.
76. Bollrath J, Phesse TJ, von Burstin VA, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15: 91-102.
77. Ernst M, Najdovska M, Grail D, et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 2008; 118: 1727-38.
78. Jarnicki A, Putoczki T, Ernst M. Stat3: linking inflammation to epithelial cancer-more than a "gut" feeling? Cell Div 2010; 5: 14.
79. Feldmann M. Translating molecular insights in autoimmunity into effective therapy. Annu Rev Immunol 2009; 27: 1-27.
80. Kollias G, Kontoyiannis D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 2002; 13: 315-21.
81. Kruglov AA, Kuchmiy A, Grivennikov SI, Tumanov AV, Kuprash DV, Nedospasov SA. Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: mouse models. Cytokine Growth Factor Rev 2008; 19: 231-44.
82. Williams RO, Paleolog E, Feldmann M. Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases. Curr Opin Pharmacol 2007; 7: 412-7.
83. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009; 9: 361-71.
84. Grivennikov SI, Kuprash DV, Liu ZG, Nedospasov SA. Intracellular signals and events activated by cytokines of the tumor necrosis factor superfamily: From simple paradigms to complex mechanisms. Int Rev Cytol 2006; 252: 129-61.
85. Matthews CP, Colburn NH, Young MR. AP-1 a target for cancer prevention. Curr Cancer Drug Targets 2007; 7: 317-24.
86. Atreya I, Neurath MF. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. Expert Rev Anticancer Ther 2008; 8: 561-72.
87. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003; 3: 276-85.
88. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
89. Schoppmann SF, Birner P, Stockl J, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002; 161: 947-56.
90. Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res 2011; 1: 482-97.
91. Zeisberg M, Strutz F, Muller GA. Role of fibroblast activation in inducing interstitial fibrosis. J Nephrol 2000; 13 Suppl 3: S111-20.
92. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-48.
93. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell 2009; 139: 871-90.
94. Kanneganti TD, Ozoren N, Body-Malapel M, et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006; 440: 233-6.
95. Rathinam VA, Vanaja SK, Fitzgerald KA. Regulation of inflammasome signaling. Nat Immunol 2012; 13: 333-2.
96. Bauer C, Duewell P, Mayer C, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 2010; 59: 1192-9.
97. Zaki MH, Lamkanfi M, Kanneganti TD. The Nlrp3 inflammasome: contributions to intestinal homeostasis. Trends Immunol 2011; 32: 171-9.
98. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 2012; 13: 343-51.
99. Sansonetti PJ. Host-bacteria homeostasis in the healthy and inflamed gut. Curr Opin Gastroenterol 2008; 24: 435-9.
100. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005; 307: 1920-5.
101. Maynard CL, Weaver CT. Intestinal effector T cells in health and disease. Immunity 2009; 31: 389-400.
102. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology 2009; 136: 65-80.
103. Coombes JL, Powrie F. Dendritic cells in intestinal immune regulation. Nat Rev Immunol 2008; 8: 435-46.
104. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-4.
105. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-66.
106. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58: 3491-4.
107. Kemp RA, Black MA, McCall J, et al. T cell subpopulations in lymph nodes may not be predictive of patient outcome in colorectal cancer. J Exp Clin Cancer Res 2011; 30: 78.
108. Ley RE, Hamady M, Lozupone C, et al. Evolution of mammals and their gut microbes. Science 2008; 320: 1647-51.
109. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007; 449: 804-10.
110. Walker AW, Ince J, Duncan SH, et al. Dominant and dietresponsive groups of bacteria within the human colonic microbiota. ISME J 2011; 5: 220-30.
111. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. Nature 2011; 474: 327-36.
112. Candela M, Guidotti M, Fabbri A, Brigidi P, Franceschi C, Fiorentini C. Human intestinal microbiota: cross-talk with the host and its potential role in colorectal cancer. Crit Rev Microbiol 2011; 37: 1-14.
113. Sonnenburg JL, Chen CT, Gordon JI. Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host. PLoS Biol 2006; 4: e413.
114. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9: 313-23.
115. Sansonetti PJ, Di Santo JP. Debugging how bacteria manipulate the immune response. Immunity 2007; 26: 149-61.
116. Jia W, Li H, Zhao L, Nicholson JK. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov 2008; 7: 123-9.
117. Rawls JF. Enteric infection and inflammation alter gut microbial ecology. Cell Host Microbe 2007; 2: 73-4.
118. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480-4.
119. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-31.
120. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007; 104: 13780-5.
121. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008; 105: 16731-6.
122. Davis CD, Milner JA. Gastrointestinal microflora, food components and colon cancer prevention. J Nutr Biochem 2009; 20: 743-52.
123. Mai V, McCrary QM, Sinha R, Glei M. Associations between dietary habits and body mass index with gut microbiota composition and fecal water genotoxicity: an observational study in African American and Caucasian American volunteers. Nutr J 2009; 8: 49.
124. O'Keefe SJ. Nutrition and colonic health: the critical role of the microbiota. Curr Opin Gastroenterol 2008; 24: 51-8.
125. O'Keefe SJ, Ou J, Aufreiter S, et al. Products of the colonic microbiota mediate the effects of diet on colon cancer risk. J Nutr 2009; 139: 2044-8.
126. Scanlan PD, Shanahan F, Clune Y, et al. Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ Microbiol 2008; 10: 789-98.
127. Uronis JM, Muhlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. Modulation of the intestinal microbiota alters colitisassociated colorectal cancer susceptibility. PLoS One 2009; 4: e6026.
128. Obe G, Anderson D. International Commission for Protection against Environmental Mutagens and Carcinogens. ICPEMC Working Paper No. 15/1. Genetic effects of ethanol. Mutat Res 1987; 186: 177-200.
129. Carman RJ, Van Tassell RL, Kingston DG, Bashir M, Wilkins TD. Conversion of IQ, a dietary pyrolysis carcinogen to a direct-acting mutagen by normal intestinal bacteria of humans. Mutat Res 1988; 206: 335-42.
130. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006; 47: 241-59.
131. Costarelli V. Bile acids as possible human carcinogens: new tricks from an old dog. Int J Food Sci Nutr 2009: 1-10.
132. Hope ME, Hold GL, Kain R, El-Omar EM. Sporadic colorectal cancer--role of the commensal microbiota. FEMS Microbiol Lett 2005; 244: 1-7.
133. Huycke MM, Gaskins HR. Commensal bacteria, redox stress, and colorectal cancer: mechanisms and models. Exp Biol Med (Maywood) 2004; 229: 586-97.
134. Franco AT, Israel DA, Washington MK, et al. Activation of betacatenin by carcinogenic Helicobacter pylori. Proc Natl Acad Sci U S A 2005; 102: 10646-51.
135. Suzuki M, Mimuro H, Kiga K, et al. Helicobacter pylori CagA phosphorylation-independent function in epithelial proliferation and inflammation. Cell Host Microbe 2009; 5: 23-34.
136. Oldani A, Cormont M, Hofman V, et al. Helicobacter pylori counteracts the apoptotic action of its VacA toxin by injecting the CagA protein into gastric epithelial cells. PLoS Pathog 2009; 5: e1000603.
137. Arthur JC, Perez-Chanona E, Muhlbauer M, et al. Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota. Science 2012.
138. Hsu RY, Chan CH, Spicer JD, et al. LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. Cancer Res 2011; 71: 1989-98.
139. Humblot C, Lhoste E, Knasmuller S, et al. Protective effects of Brussels sprouts, oligosaccharides and fermented milk towards 2-amino-3-methylimidazo[4,5-f]quinoline (IQ)-induced genotoxicity in the human flora associated F344 rat: role of xenobiotic metabolising enzymes and intestinal microflora. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 802: 231-7.
140. Kurdi P, Tanaka H, Van Veen HW, Asano K, Tomita F, Yokota A. Cholic acid accumulation and its diminution by short-chain fatty acids in bifidobacteria. Microbiology 2003; 149: 2031-7.
141. Kurdi P, van Veen HW, Tanaka H, et al. Cholic acid is accumulated spontaneously, driven by membrane deltapH, in many lactobacilli. J Bacteriol 2000; 182: 6525-8.
142. Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 2009; 294: 1-8.
143. McMahon B, Kwaan HC. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 2008; 36: 184-94.
144. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512-9.
145. Pedron T, Sansonetti P. Commensals, bacterial pathogens and intestinal inflammation: an intriguing menage a trois. Cell Host Microbe 2008; 3: 344-7.
146. Brocklehurst JC. Bowel management in the neurologically disabled. The problems of old age. Proc R Soc Med 1972; 65: 66-9.
147. Flint HJ, Duncan SH, Scott KP, Louis P. Interactions and competition within the microbial community of the human colon: links between diet and health. Environ Microbiol 2007; 9: 1101-11.
148. Guigoz Y, Dore J, Schiffrin EJ. The inflammatory status of old age can be nurtured from the intestinal environment. Curr Opin Clin Nutr Metab Care 2008; 11: 13-20.
149. Larbi A, Franceschi C, Mazzatti D, Solana R, Wikby A, Pawelec G. Aging of the immune system as a prognostic factor for human longevity. Physiology (Bethesda) 2008; 23: 64-74.
150. Macfarlane GT, Cummings JH, Macfarlane S, Gibson GR. Influence of retention time on degradation of pancreatic enzymes by human colonic bacteria grown in a 3-stage continuous culture system. J Appl Bacteriol 1989; 67: 520-7.
151. Baggio G, Donazzan S, Monti D, et al. Lipoprotein(a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors. FASEB J 1998; 12: 433-7.
152. Passeri G, Pini G, Troiano L, et al. Low vitamin D status, high bone turnover, and bone fractures in centenarians. J Clin Endocrinol Metab 2003; 88: 5109-15.
153. Cea M CA, Gobbi M, Patrone F, et al. New Insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des 2013; 19(4): 734-44.
154. Andreoli F BA, Parenti MD, Del Rio A. Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des 2013; 19(4): 578-613.
155. Davis CD, Uthus EO. DNA methylation, cancer susceptibility, and nutrient interactions. Exp Biol Med (Maywood) 2004; 229: 988-95.
156. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-59.
157. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3: 253-66.
158. Foran E, Garrity-Park MM, Mureau C, et al. Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6. Mol Cancer Res 2010; 8: 471-81.
159. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41: 178-86.
160. Yagi S, Hirabayashi K, Sato S, et al. DNA methylation profile of tissue-dependent and differentially methylated regions (T-DMRs) in mouse promoter regions demonstrating tissue-specific gene expression. Genome Res 2008; 18: 1969-78.
161. Reed K, Poulin ML, Yan L, Parissenti AM. Comparison of bisulfite sequencing PCR with pyrosequencing for measuring differences in DNA methylation. Anal Biochem 2010; 397: 96-106.
162. Berman BP, Weisenberger DJ, Aman JF, et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet 2012; 44: 40-6.
163. Clark SJ. Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis. Hum Mol Genet 2007; 16 Spec No 1: R88-95.
164. Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 2006; 38: 540-9.
165. Stransky N, Vallot C, Reyal F, et al. Regional copy numberindependent deregulation of transcription in cancer. Nat Genet 2006; 38: 1386-96.
166. Rakyan VK, Down TA, Maslau S, et al. Human aging-associated DNA hypermethylation occurs preferentially at bivalent chromatin domains. Genome Res 2010; 20: 434-9.
167. Calvanese V, Lara E, Kahn A, Fraga MF. The role of epigenetics in aging and age-related diseases. Ageing Res Rev 2009; 8: 268-76.
168. Kamiyama H, Suzuki K, Maeda T, et al. DNA demethylation in normal colon tissue predicts predisposition to multiple cancers. Oncogene 2012.
169. Chang E, Park DI, Kim YJ, et al. Detection of colorectal neoplasm using promoter methylation of ITGA4, SFRP2, and p16 in stool samples: a preliminary report in Korean patients. Hepatogastroenterology 2010; 57: 720-7.
170. Chen WD, Han ZJ, Skoletsky J, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 2005; 97: 1124-32.
171. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 2010; 29: 181-206.
172. Kim MS, Louwagie J, Carvalho B, et al. Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer. PLoS One 2009; 4: e6555.
173. Muller HM, Oberwalder M, Fiegl H, et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 2004; 363: 1283-5.
174. Zhang W, Bauer M, Croner RS, et al. DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene. Dis Colon Rectum 2007; 50: 1618-26; discussion 26-7.
175. He Q, Chen HY, Bai EQ, et al. Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer. Cancer Genet Cytogenet 2010; 202: 1-10.
176. Herbst A, Rahmig K, Stieber P, et al. Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer. Am J Gastroenterol 2011; 106: 1110-8.
177. Tang D, Liu J, Wang DR, Yu HF, Li YK, Zhang JQ. Diagnostic and prognostic value of the methylation status of secreted frizzledrelated protein 2 in colorectal cancer. Clin Invest Med 2011; 34: E88-95.
178. Tanzer M, Balluff B, Distler J, et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One 2010; 5: e9061.
179. Lind GE, Danielsen SA, Ahlquist T, et al. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer 2011; 10: 85.
180. Lind GE, Ahlquist T, Kolberg M, et al. Hypermethylated MAL gene-a silent marker of early colon tumorigenesis. J Transl Med 2008; 6: 13.
181. Lind GE, Ahlquist T, Lothe RA. DNA hypermethylation of MAL: a promising diagnostic biomarker for colorectal tumors. Gastroenterology 2007; 132: 1631-2; author reply 2.
182. Lind GE, Raiborg C, Danielsen SA, et al. SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis. Oncogene 2011; 30: 3967-78.
183. Andrews SC, Robinson AK, Rodriguez-Quinones F. Bacterial iron homeostasis. FEMS Microbiol Rev 2003; 27: 215-37.
184. de Vogel J, Jonker-Termont DS, van Lieshout EM, Katan MB, van der Meer R. Green vegetables, red meat and colon cancer: chlorophyll prevents the cytotoxic and hyperproliferative effects of haem in rat colon. Carcinogenesis 2005; 26: 387-93.
185. Pierre F, Freeman A, Tache S, Van der Meer R, Corpet DE. Beef meat and blood sausage promote the formation of azoxymethaneinduced mucin-depleted foci and aberrant crypt foci in rat colons. J Nutr 2004; 134: 2711-6.
186. Pierre F, Tache S, Petit CR, Van der Meer R, Corpet DE. Meat and cancer: haemoglobin and haemin in a low-calcium diet promote colorectal carcinogenesis at the aberrant crypt stage in rats. Carcinogenesis 2003; 24: 1683-90.
187. Sesink AL, Termont DS, Kleibeuker JH, Van der Meer R. Red meat and colon cancer: the cytotoxic and hyperproliferative effects of dietary heme. Cancer Res 1999; 59: 5704-9.
188. Young GP, St John DJ, Rose IS, Blake D. Haem in the gut. Part II. Faecal excretion of haem and haem-derived porphyrins and their detection. J Gastroenterol Hepatol 1990; 5: 194-203.
189. Dolara P, Luceri C, De Filippo C, et al. Red wine polyphenols influence carcinogenesis, intestinal microflora, oxidative damage and gene expression profiles of colonic mucosa in F344 rats. Mutat Res 2005; 591: 237-46.
190. Rowland IR, Bearne CA, Fischer R, Pool-Zobel BL. The effect of lactulose on DNA damage induced by DMH in the colon of human flora-associated rats. Nutr Cancer 1996; 26: 37-47.
191. Ong TP, Moreno FS, Ross SA. Targeting the epigenome with bioactive food components for cancer prevention. J Nutrigenet Nutrigenomics 2011; 4: 275-92.
192. Ong TP, Perusse L. Impact of nutritional epigenomics on disease risk and prevention: introduction. J Nutrigenet Nutrigenomics 2011; 4: 245-7.
193. Ross SA, Dwyer J, Umar A, et al. Introduction: diet, epigenetic events and cancer prevention. Nutr Rev 2008; 66 Suppl 1: S1-6.
194. Duthie SJ. Symposium 1: Nutrition and epigenetics Epigenetic modifications and human pathologies: cancer and CVD. Proceedings of the Nutrition Society 2011; 70: 47-56.
195. Araujo JR, Goncalves P, Martel F. Chemopreventive effect of dietary polyphenols in colorectal cancer cell lines. Nutr Res 2011; 31: 77-87.
196. Fang M, Chen D, Yang CS. Dietary polyphenols may affect DNA methylation. J Nutr 2007; 137: 223S-8S.
197. Duthie GG, Duthie SJ, Kyle JA. Plant polyphenols in cancer and heart disease: implications as nutritional antioxidants. Nutr Res Rev 2000; 13: 79-106.
198. Duthie SJ. Berry phytochemicals, genomic stability and cancer: evidence for chemoprotection at several stages in the carcinogenic process. Mol Nutr Food Res 2007; 51: 665-74.
199. Ferguson LR. Role of plant polyphenols in genomic stability. Mutat Res 2001; 475: 89-111.
200. Friso S, Choi SW, Girelli D, et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci U S A 2002; 99: 5606-11.
201. Jacob RA, Gretz DM, Taylor PC, et al. Moderate folate depletion increases plasma homocysteine and decreases lymphocyte DNA methylation in postmenopausal women. J Nutr 1998; 128: 1204-12.
202. Pufulete M, Al-Ghnaniem R, Leather AJ, et al. Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study. Gastroenterology 2003; 124: 1240-8.
203. Rampersaud GC, Kauwell GP, Hutson AD, Cerda JJ, Bailey LB. Genomic DNA methylation decreases in response to moderate folate depletion in elderly women. Am J Clin Nutr 2000; 72: 998-1003.
204. Paluszczak J, Krajka-Kuzniak V, Baer-Dubowska W. The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicol Lett 2010; 192: 119-25.